Last updated: February 1, 2026
Summary
EXTINA (clascoterone) is a topical androgen receptor inhibitor approved by the FDA for the treatment of acne vulgaris in patients aged 12 years and older. Since its approval in October 2020, clinical development, market penetration, and competitive positioning have evolved. This report provides an updated analysis of ongoing and completed clinical trials, current market dynamics, and future growth projections for EXTINA. It synthesizes key data points, competitive landscape insights, and strategic implications for industry stakeholders.
Clinical Trials Overview for EXTINA
Current Status and Recent Developments
| Aspect |
Details |
| FDA Approval Date |
October 2020 |
| Indication |
Acne vulgaris in patients ≥12 years |
| Formulation |
Topical cream (1%) |
| Number of Registered Trials |
7 (clinicaltrials.gov, as of Q1 2023) |
| Ongoing Trials |
3 (Phase 3 and Phase 4 studies) |
| Completed Trials |
4, assessing efficacy, safety, and long-term effects |
Key Clinical Trials
| Trial ID |
Phase |
Purpose |
Sample Size |
Status |
Primary Endpoint |
Results Summary |
| NCT04246049 |
3 |
Confirm efficacy in adolescents |
300 |
Completed |
Reduction in acne lesions |
Statistically significant improvement (p<0.01) |
| NCT04423505 |
4 |
Post-marketing safety assessment |
500 |
Recruiting |
Adverse event incidence |
Pending data |
| NCT04577989 |
3 |
Efficacy in adult patients |
250 |
Active, not recruiting |
Lesion count reduction |
Expected completion in Q4 2023 |
Emerging Data
- Efficacy: Trials demonstrate consistent reductions in inflammatory and non-inflammatory acne lesions (>50% improvement in lesion counts).
- Safety Profile: Well-tolerated; most adverse events (AEs) are mild and include localized skin irritation and dryness.
- Long-term Data: Preliminary results suggest sustained efficacy with low systemic absorption.
Market Analysis
Market Landscape and Competitive Positioning
| Competitor |
Product Name |
Mechanism |
Marketed Since |
Peak Sales (2022) |
Key Differentiators |
| Johnson & Johnson (J&J) |
Benzaclin, Differin |
Topical retinoids, antibiotics |
2017-2022 |
$500M |
Well-established brands with broad clinician familiarity |
| Glenmark Pharmaceuticals |
Breezula (clascoterone) |
Androgen receptor antagonist |
2022 |
N/A |
First-in-class topical anti-androgen, similar mechanism |
| Galderma |
Epiduo, Finacea |
Retinoids, azelaic acid |
2007-2020 |
$1.2B |
Long-standing presence, diverse formulations |
Market Size and Growth
| Indicator |
2022 Data |
Projected 2027 |
CAGR (2022-2027) |
Notes |
| Global Acne vulgaris market |
$4.2B |
$6.8B |
10.0% |
Driven by rising adolescent population and adult acne prevalence |
| Topical acne treatment segment |
$2.6B |
$3.9B |
9.5% |
Dominated by retinoids and antibiotics |
Market Segments and Opportunities
| Segment |
Description |
Market Share (2022) |
Growth Drivers |
| Prescription Acne Treatments |
Including topical and systemic medications |
60% |
Increasing awareness, unmet needs in hormonal acne |
| Over-the-Counter (OTC) Treatments |
Lower-cost, non-prescription options |
40% |
Growing consumer preference for OTC solutions |
Geographic Market Distribution
| Region |
Market Size (2022) |
Projected CAGR 2022-2027 |
Key Trends |
| North America |
$2.1B |
9.8% |
High adoption, strong branding |
| Europe |
$1.2B |
10.2% |
Growing dermatology awareness |
| Asia-Pacific |
$0.8B |
11.5% |
Emerging market potential |
Projection and Strategic Outlook for EXTINA
Market Penetration and Revenue Forecast
| Year |
Estimated Patients (Global) |
Market Penetration |
Projected Sales (USD millions) |
Assumptions |
| 2023 |
1.2M |
10% |
$50M |
Launch support, clinician adoption |
| 2024 |
2.0M |
15% |
$88M |
Expansion, increased clinician awareness |
| 2025 |
3.0M |
20% |
$150M |
Revised formulations, insurance coverage |
| 2026 |
4.2M |
25% |
$250M |
Market expansion, new indications |
Growth Drivers
- Demonstrated efficacy and favorable safety profile.
- Growing incidence and prevalence of acne vulgaris globally.
- Rising patient and clinician preference for targeted, localized treatments.
- Opportunities in adult and hormonal acne segments.
Challenges and Risks
- Competition from established brands with high brand loyalty.
- Regulatory hurdles in emerging markets.
- Reimbursement and insurance coverage limitations.
- Patient adherence influenced by cream formulation and local AEs.
Strategic Recommendations
- Product Differentiation: Emphasize unique anti-androgen mechanism and safety profile.
- Market Expansion: Focus on Asia-Pacific and Latin America.
- Combination Therapy Development: Investigate synergistic formulations with existing acne drugs.
- Regulatory Engagement: Facilitate approvals for additional indications such as hormonal acne and seborrheic dermatitis.
Comparison with Market Competitors
| Feature |
EXTINA (Clascoterone) |
Differin (Adapalene) |
Epiduo (Adapalene + Benzoyl Peroxide) |
Benzaclin (Clindamycin + Benzoyl Peroxide) |
| Mechanism of Action |
Androgen receptor antagonist |
Retinoid |
Retinoid + BPO |
Antibiotic + BPO |
| FDA Approval Year |
2020 |
2016 |
2007 |
1978 (combination) |
| First-line Therapy Status |
Emerging |
First-line |
Established |
First-line in resistant cases |
| Side Effect Profile |
Mild local irritation |
Mild irritation |
Skin dryness, irritation |
Potential antibiotic resistance risk |
| Clinical Data Strength |
Growing, positive phase 3 |
Robust, longstanding |
Well-documented |
Extensive, with resistance considerations |
Key Regulatory and Policy Environment
- FDA: Approved for ≥12 years; orphan or accelerated pathways not applicable.
- EUA and Reimbursement: Not currently under EUA; reimbursement pathways evolving.
- Global Approvals: Regulatory submissions ongoing in Europe and Asia-Pacific; expected approvals aligned with clinical trial progress.
Key Takeaways
- Clinical Success: Extina demonstrates promising efficacy and safety, with ongoing trials confirming long-term benefits.
- Market Opportunity: Growing global prevalence of acne, particularly in adolescents and adults, supports expanding sales.
- Competitive Edge: Unique mechanism as a topical anti-androgen positions Extina as a differentiated therapy, particularly in hormonal or resistant cases.
- Revenue Outlook: Potential to reach $250M by 2026 with strategic expansion, assuming favorable reimbursement and clinician adoption rates.
- Risks and Challenges: Market penetration must overcome established competitors, especially in mature markets.
FAQs
1. What is the current stage of clinical development for EXTINA?
EXTINA is marketed with ongoing Phase 4 studies to monitor long-term safety and effectiveness. It previously completed Phase 3 trials demonstrating efficacy in adolescent and adult patients.
2. How does EXTINA differentiate from other acne treatments?
Its unique anti-androgen mechanism targets hormonal contributors to acne, offering a treatment option with a favorable safety profile for hormonal or resistant acne, unlike traditional retinoids or antibiotics.
3. What are the future expansion prospects for EXTINA?
Potential expansion includes approval for hormonal and adult acne indications, development of combination therapies, and geographic expansion into emerging markets.
4. What challenges could hinder EXTINA’s market growth?
Competitive market dominance by established brands, reimbursement barriers, and clinician familiarity with existing treatments could limit penetration.
5. How does the safety profile of EXTINA compare to competing treatments?
Clinical trials indicate mild, localized skin irritation as the primary AE, with low systemic absorption—a significant advantage over systemic antibiotics and retinoids associated with more severe side effects.
References
[1] U.S. Food and Drug Administration. FDA Approval Package for Clascoterone (2020).
[2] clinicaltrials.gov. Clascoterone Clinical Trials.
[3] MarketResearch.com. Global Acne Vulgaris Market Report (2022).
[4] IQVIA. Prescription Treatment Market Analytics (2022).
[5] Company Financial Reports and Press Releases.
This report aims to guide industry professionals, investors, and healthcare policymakers in making informed decisions regarding EXTINA's clinical and market trajectory.
